December 2016
The global newborn screening market is expected to reach USD XX million by 2021, growing at a CAGR of XX%. Newborn screening is performed to screen infants after birth for the detection of any health conditions or diseases that can be fatal but are not detected during birth. The newborn screening tests are basically an evaluation of metabolites and blood samples. These tests vary according to different country jurisdictions. In many areas, newborn screening tests include screening for hearing loss and congenital heart disease. The major diseases screened for are sickle cell disease, cystic fibrosis, newborn hearing loss, congenital hypothyroidism, phenyl ketone urea and congenital heart disease.
Global Newborn Screening Market- Market Dynamics
The report details several driving and restraining factors for the global newborn screening market. Some of them are listed below.
Drivers
Restraints
The global newborn screening market has been segmented based on technology, product, test type, and geography. The segmentation based on technology has been subdivided into tandem mass spectrometry, DNA-based assay, enzyme, and immunoassays, electrophoresis, hearing screening technology, and pulse oximetry technology. The segmentation based on product is sub-divided into newborn disorder screening instruments, hearing screening devices and accessories, pulse oximetry, and reagents and assay kits. The segmentation based on test type has been sub-divided into critical congenital heart disease test, hearing screening test, and dry blood spot test.
Amongst technologies being used, tandem mass spectrometry is expected to have the highest growth rate during the forecast period. The dry blood spot test has the largest market share in the segment by test type.
Based on geography, the global newborn screening test market has been segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, and South America. The segmentation on North America discusses different market trends, and market size of newborn screening tests in the USA, Canada, and Mexico. The Europe segment has been further subdivided into UK, France, Italy, Germany, Benelux, Scandinavia, Spain and Portugal. The segmentation on Asia-Pacific has been subdivided into China, Japan, India, South Korea, Australia, and New Zealand. The Middle-east & North Africa segment includes GCC, Egypt, and others. The South America region includes Brazil, Argentina, Colombia and others.
Some of the key players in the market are:
What the Report Offers
.png)
